Cosela
(Trilaciclib)ApprovedSmall molecule
Trilaciclib is used to help protect bone marrow and reduce severe blood cell damage in cancer patients receiving chemotherapy, which helps patients recover faster and reduces the need for blood transfusions.[2] Cosela is currently approved and in use across 19 indications[4].[1]
Cosela is one of 488 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Approved.
19
Indications
33
Total Trials
19
Active Trials
487
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
14
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 19 indications
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Cosela
PPharmacosmos A/S
Approved
Blenoxane
Bristol-Myers SquibbPreclinical
Lexiscan
AstellasPreclinical
Voltaren
NovartisPreclinical
Zolymbus
AbbViePreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Spravato
WWim Janssens
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Small Cell Lung Cancer6 trials
Show 3 more trials
Breast Cancer4 trials
Triple-Negative Breast Cancer2 trials
Myelosuppression2 trials
Trilaciclib Prevents Myelosuppression With Chemoradiotherapy
Recruiting·—·Phase 2·NCT06490081·40 enrolled
16 more indications
Chemotherapy2 trials
Bladder Cancer1 trial
CDK4/6 Inhibitor1 trial
Metastatic Colorectal Cancer1 trial
Head and Neck Squamous Cell Carcinoma1 trial
Non-Small Cell Lung Cancer1 trial
Advanced NSCLC1 trial
Lung Cancer1 trial
Esophageal Cancer1 trial
Trilaciclib Combined With Concurrent Chemoradiotherapy and Immunotherapy in the Treatment of Esophageal Cancer
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06569459·60 enrolled
Anti-PD-1 Antibody1 trial
Metastatic Triple-negative Breast Cancer1 trial
Tumor Patients1 trial
A Single-arm, Multi-center, Phase II Exploratory Clinical Study to Evaluate the Efficacy and Safety of Trilaciclib in Preventing Myelosuppression Caused by Topoisomerase I Inhibitor Type ADC Drugs
Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Preclinical·NCT07736001·96 enrolled
Squamous Cell Carcinoma1 trial
A Prospective, Single-Arm, Phase II Trial of Trilaciclib Combined With Immunotherapy and Chemotherapy as First-Line Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT07679997·32 enrolled
Regulatory
FDA Approval Timeline[5]
Feb 12, 2021
COSELA
NDA NDA214200
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Cosela drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Trilaciclib. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]FDA Orange Book — Patent and exclusivity data for Cosela. U.S. Food & Drug Administration.
- [7]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Cyclin-Dependent Kinase 6 Inhibitor; Cyclin-Dependent Kinase 4 Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- PPharmacosmos A/S